tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Anebulo Pharmaceuticals Announces Plan to Go Private

Story Highlights
  • Anebulo Pharmaceuticals plans to go private with a reverse stock split approved by its Board.
  • The reverse stock split aims to reduce stockholders, allowing deregistration as an SEC reporting company.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Anebulo Pharmaceuticals Announces Plan to Go Private

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Anebulo Pharmaceuticals ( (ANEB) ) has issued an announcement.

On July 23, 2025, Anebulo Pharmaceuticals announced a plan to go private by implementing a reverse stock split, approved by its Board of Directors, with a ratio between 1-for-2,500 and 1-for-7,500. This move aims to reduce the number of stockholders to qualify for deregistration as an SEC reporting company, with stockholders owning fewer than the minimum number of shares receiving a cash payment of $3.50 per share. The transaction is intended to reduce operating costs and maximize shareholder value, although the Board retains the right to abandon the plan if deemed not in the best interest of the company or its stockholders.

The most recent analyst rating on (ANEB) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Anebulo Pharmaceuticals stock, see the ANEB Stock Forecast page.

Spark’s Take on ANEB Stock

According to Spark, TipRanks’ AI Analyst, ANEB is a Underperform.

Anebulo Pharmaceuticals is struggling financially, with no revenue generation and consistent losses. The technical indicators reflect a bearish trend, with the stock trading below key moving averages. Valuation metrics are weak due to negative earnings. While the balance sheet is strong with no debt, the heavy reliance on financing activities poses a risk. Investors should be cautious and consider the company’s ability to achieve profitability and secure future funding.

To see Spark’s full report on ANEB stock, click here.

More about Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing novel solutions for cannabis-induced toxicity. Its lead product candidate, selonabant, is being developed to treat acute cannabinoid intoxication, with a focus on a faster approval timeline for a pediatric intravenous formulation.

Average Trading Volume: 14,620

Technical Sentiment Signal: Buy

Current Market Cap: $75.19M

For an in-depth examination of ANEB stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1